Divi's Laboratories (Divi's)

Transcription

1 Divi's Laboratories (Divi's) Institutional Equity Research Pharma India DIVI IN; DIVI.BO November 3, QF15 result review HOLD Weak F15 + Full valuation = Downgrade to Hold Current price (31 Oct) Rs 1,872 Target price Rs 1,885 Upside/(downside) % 1 Earning estimate Revised Market data Mkt capitalisation Rs bn Average daily vol ' week H/L Rs 1888 / 977 Shares O/S mn Free float mn 63.6 Promotor holding % 52.1 Foreign holding % 19.1 Face value Rs 2.0 Price performance (%) 1m 3m 6m 1yr Nifty (abs) Stock (abs) Relative to Index (3.2) Performance (Rs) Nov-13 Feb-14 May-14 Jul-14 Oct-14 Divi's Lab. (LHS) Source: Bloomberg, SSLe (%) Rel. to BSETHC (RHS) Divi s Laboratories (Divi s) reported exceptional sales and disappointed operating margins in 2QF15. Sales and adjusted profits grew 47% and 30% YoY to Rs8.3bn and Rs2.3bn, respectively. Strong sales largely resulted from bunching up of orders, which should normalize in 2H (F15e growth guidance intact ~21%). EBITDAM at 36.6% is weak (SSLe of 37% and consensus of 38%), dragged from lower gross margins of 57.8%, as the sales mix from CCS business dipped to 46% (47% in 1Q). We downgrade Divi s to HOLD with price target Rs1,885 (20x rollover forward valuation). Model changes: In view of tepid OPM for 1H, 36.6% and weak margin commentary for 2H, we lower EPS forecast for F15e by 5.7%. We also model for F17e with sales at Rs46.5bn (23% growth over F16e) and profits at Rs13.7bn (26% growth over F16e). Management commentary: While 21% sales growth is projected for F15e, the guidance on OPM is cut down to % (earlier 38%). In the short term, adverse business mix (low margin Generic API sales) and Vizag plant shutdown (Hudhud cyclone) have impacted the operating results, although 38 39% longterm margin will sustain. Utilisation of DSN facility appears to be normalizing. Tax rate guidance is about 21 22%. Other highlights: Forex gain during 2Q was Rs43mn included in other income. Contribution from Top 5 products remained stable at 46% of sales. Nutraceutical sales came at Rs440mn (Rs870mn in 1H). Downgrade to HOLD; price target Rs1,885: Moderation in the near-term business outlook and full valuation lead us to downgrade Divi s to HOLD from BUY. On our new EPS, P/E is at 31x for F15e and 23x for F16e, respectively. However, in the longer term we are positive on business fundamentals as we forecast elevated two-year EPS CAGR at 31% (F15e F17e) and expect high degree of operative leverage to converge into improved capital returns ratio. We raise our P/E multiple to 20x on 1-year forward EPS with DSN utilisation getting normalized. Our new price target is Rs1,885 (based on 20x rollover forward valuation on October 14). Vivek Kumar vivek.kumar@sbicapsec.com Aarti Rao aarti.rao@sbicapsec.com Financial summary Y/E March (Rs mn) F13 F14 F15e F16e F17e Net sales 21,448 25,140 30,615 37,687 46,479 growth (%) EBITDA margin (%) Adjusted net profit 5,906 7,413 8,002 10,872 13,662 EPS (Rs) growth (%) P/E (x) EV/EBITDA (x) Dividend yield (%) RoE (%) RoCE (%) Source: Company, SSLe SBICAP Research on Bloomberg SBICAP <GO>, Please refer to our disclaimer given at the last page.

2 Boost from bunched up orders exceptional in nature Weak margins Forex gain Quarterly financials Y/E March (Rs mn) 2QF15 2QF14 YoY (%) 1QF15 QoQ (%) 2QF15e Var. (%) Net sales 8,298 5, , , Cost of goods 3,506 1,802 2,489 2,746 Employee benefits exp Other Expenses 1, ,056 EBITDA 3,034 2, , , EBITDAM (%) Depreciation and amort EBIT 2,742 2, , , EBITM (%) Other income Interest expenses Extraordinary/Exceptional Profit before tax 2,927 2, , , Tax expense Effective tax rate (%) PAT 2,296 2, , , Minority interest Reported net profit 2,296 2, , , Non-recurring items Adj. net profit 2,253 1, , , NPM (%) EPS (Rs) Source: Company, SSLe vivek.kumar@sbicapsec.com I aarti.rao@sbicapsec.com November 3,

3 Change in estimates: We have slashed our F15e EPS by 5.7% and decreased our F15e gross margin assumption by 270bps (due to on going adverse business mix into high generic API sales). This has compressed EBITDAM for F15e. Estimate revision (Rs mn) Revised Old Change (%) F15e F16e F15e F16e F15e F16e Sales 30,615 37,687 30,615 37, EBITDA 11,183 14,897 12,010 14,897 (6.9) 0.0 EBITDA margin (%) (270) bps 0 bps Adj. PAT 8,002 10,872 8,482 10,810 (5.7) 0.6 Source: SSLe Key assumptions Y/E Mar F 15e F 16e F 17e Generic APIs growth (%) CCS growth (%) US$/Rs Gross margin (%) Staff cost % to sales R&D spend % to sales Tax rate (%) Source: SSLe P/E distribution (1-year forward) We downgrade Divi s to HOLD with price target Rs1,885 (20x rollover forward valuation) (x) SD = Mean = SD = Apr-07 Jul-07 Oct-07 Jan-08 Apr-08 Jul-08 Oct-08 Jan-09 Apr-09 Jul-09 Oct-09 Jan-10 Apr-10 Jul-10 Oct-10 Jan-11 Apr-11 Jul-11 Oct-11 Jan-12 Apr-12 Jul-12 Oct-12 Jan-13 Apr-13 Jul-13 Oct-13 Jan-14 Apr-14 Jul-14 Oct-14 Source: Bloomberg, SSLe November 3,

4 Financials Income Statement Balance Sheet Y/E Mar (Rsmn) F13 F14 F15e F16e F17e Y/E Mar (Rsmn) F13 F14 F15e F16e F17e Net sales 21,448 25,140 30,615 37,687 46,479 Cash & Bank balances ,515 4,574 7,221 growth (%) Other Current assets 14,154 17,583 19,250 23,572 28,940 Operating expenses 13,297 14,951 19,432 22,790 28,106 Investments 4,078 5,046 6,308 7,885 9,856 EBITDA 8,152 10,189 11,183 14,897 18,372 growth (%) Net fixed assets 12,121 13,661 13,819 13,901 13,909 Depreciation &amortisation ,342 1,417 1,492 Goodwill & intangible assets EBIT 7,382 9,268 9,841 13,480 16,880 Other non-current assets 625 1,190 1,190 1,190 1,190 Other income Total assets 31,388 37,838 43,081 51,122 61,117 Interest paid Extraordinary/Exceptional items Current liabilities 4,957 6,375 6,742 8,148 9,804 PBT 7,812 10,086 10,294 13,938 17,515 Borrowings Tax 1,792 2,169 2,252 3,066 3,853 Other non-current liabilities 816 1,249 1,217 1,217 1,217 Effective tax rate (%) Total liabilities 6,167 7,808 8,142 9,549 11,205 Net profit 6,020 7,917 8,042 10,872 13,662 Minority interest Share capital Reported Net profit 6,020 7,917 8,042 10,872 13,662 Reserves & surplus 24,955 29,765 34,673 41,308 49,646 Non-recurring items (115) (504) (40) - - Shareholders' funds 25,221 30,030 34,938 41,574 49,912 Adjusted Net profit 5,906 7,413 8,002 10,872 13,662 Minority interest growth (%) Total equity & liabilities 31,388 37,838 43,081 51,122 61,117 Key Financials ratios Cash Flow Statement Y/E Mar F13 F14 F15e F16e F17e Y/E Mar (Rsmn) F13 F14 F15e F16e F17e Profitability and return ratios (%) Pre-tax profit 7,812 10,086 10,294 13,938 17,515 EBITDAM Depreciation ,342 1,417 1,492 EBITM Chg in working capital (1,409) (2,569) (1,332) (2,916) (3,711) NPM Total tax paid (1,609) (1,818) (2,252) (3,066) (3,853) RoE Other operating activities RoCE Operating CF 5,554 6,585 8,053 9,373 11,443 RoIC Capital expenditure (3,681) (2,425) (1,500) (1,500) (1,500) Chg in investments 692 (968) (1,262) (1,577) (1,971) Per share data (Rs) Other investing activities O/s shares (mn) Investing CF (2,989) (3,393) (2,762) (3,077) (3,471) EPS FCF 2,565 3,192 5,291 6,296 7,972 FDEPS Equity raised/(repaid) CEPS Debt raised/(repaid) (136) (209) (0) - - BV Dividend (incl. tax) (2,329) (3,106) (3,134) (4,237) (5,324) DPS Other financing activities (0) (0) Financing CF (2,466) (3,243) (3,134) (4,237) (5,324) Valuation ratios (x) Net chg in cash & bank bal. 100 (51) 2,157 2,059 2,648 PE Closing cash & bank bal ,515 4,574 7,221 P/BV EV/EBITDA EV/Sales Other key ratios D/E (x) DSO (days) Du Pont Analysis - RoE NPM (%) Asset turnover (x) Equity multiplier (x) RoE (%) Source: Company, SSLe November 3,

5 Recommendation History (Rs) BUY HOLD SELL Stock Price Target Price Date Stock Price TP Rec. 7-Feb-13 1,064 1,393 BUY 4-Mar-13 1,041 1,393 BUY 20-May-13 1,082 1,323 BUY 2-Aug ,323 BUY 8-Nov-13 1,020 1,367 BUY 3-Feb-14 1,313 1,551 BUY 23-May-14 1,296 1,575 BUY 14-Aug-14 1,461 1,690 BUY 31-Oct-14 1,872 1,885 HOLD 800 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13 Oct-13 Nov-13 Dec-13 Jan-14 Feb-14 Mar-14 Apr-14 May-14 Jun-14 Jul-14 Aug-14 Sep-14 Oct-14 Nov-14 Source: Bloomberg, SSLe SBICAP Securities Limited Corporate Office: Mafatlal Chambers, A-Wing, 2nd Floor, N. M. Joshi Marg, Lower Parel, Mumbai Tel.: /01 Fax: KEY TO INVESTMENT RATINGS (w.e.f. February 2013) Guide to the expected return over the next 12 months. 1=BUY (expected to give absolute returns of 15 or more percentage points); 2=HOLD (expected to give absolute returns between -10 to 15 percentage points); 3=SELL (expected to give absolute returns less then -10 percentage points) DISCLAIMER We, Vivek Kumar MBA (Finance) Analyst and Aarti Rao MMS (Finance) - Associate authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer(s) or securities. This report has been prepared based upon information available to the public and sources, believed to be reliable. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. SBICAP Securities Limited (SSL),a full service Stock Broking Company and a member of National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Ltd. (BSE). SSL is a wholly owned subsidiary of SBI Capital Markets Limited (SBICAP), which is engaged into the investment banking activities and is registered with the Securities and Exchange Board of India as a Category I Merchant Banker. SBICAP (Singapore) Limited, a fellow subsidiary of SSL, incorporated in Singapore is regulated by the Monetary Authority of Singapore as a holder of a capital markets services license and an exempt financial adviser in Singapore. SBICAP (Singapore) Limited s services are available only to accredited investors (other than individuals), and institutional investors in Singapore as defined in section 4A of the Securities and Futures Act (Cap. 289) of Singapore. SBICAP (Singapore) is a wholly owned subsidiary of SBICAP. SBICAP (UK) Limited, a fellow subsidiary of SSL, incorporated in United Kingdom is authorised and regulated by the Financial Services Authority. [SBICAP, SBICAP (Singapore) Limited, SBICAP (UK) Limited and SSL are collectively referred to as SBICAP Entities]. Recipients of this report should assume that SBICAP Entities (and/or its Affiliates) is seeking (or may seek or will seek) Investment Banking, advisory, project finance or other businesses and may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of this material/ report. SSL (and/or its Affiliates) and its officers, directors and employees, including the analysts and others involved in the preparation/issuance of this material and their dependant(s), may on the date of this report/from time to time, have long/short positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. SSL s sales people, dealers, traders and other professionals may provide oral or written market commentary or trading strategies to its clients that reflect opinion that are contrary to the opinions expressed herein, and its proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. SSL may have earlier issued or may issue in future reports on the companies covered herein with recommendations/ information inconsistent or different from those made in this report. In reviewing this document, you should be aware that any or all of the foregoing, among other things, may give rise to potential conflicts of interest. Please ensure that you have read Risk Disclosure Document for Capital Market and Derivatives Segments as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. The projections and forecasts described in this report should be carefully evaluated as these 1. Are based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. 2. Can be expected that some of the estimates on which these were based, will not materialize or will vary significantly from actual results, and such variances may increase over time. 3. Are not prepared with a view towards compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these. 4. Should not be regarded, by mere inclusion in this report, as a representation or warranty by or on behalf of SSL the authors of this report, or any other person, that these or their underlying assumptions will be achieved. This report is for information purposes only and SBICAP Entities accept no liabilities for any loss or damage of any kind arising out of the use of this report. Though disseminated to clients simultaneously, not all clients may receive this report at the same time. SSL will not treat recipients as clients by virtue of their receiving this report. It should not be construed as an offer to sell or solicitation of an offer to buy, purchase or subscribe to any securities this report November 3,

6 shall not form the basis of or be relied upon in connection with any contract or commitment, whatsoever. This report does not solicit any action based on the material contained herein. It does not constitute a personal recommendation and does not take into account the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this report may not be suitable for all the investors. SSL does not provide tax advice to its clients and you should independently evaluate the suitability of this report and all investors are strongly advised to seek professional consultation regarding any potential investment. Nothing in this report is intended by SBICAP Entities to be construed as legal, accounting or tax advice. Certain transactions including those involving futures, options, and other derivatives as well as non-investment grade securities give rise to substantial risk and are not suitable for all investors. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. Investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk. The price, value and income of the investments referred to in this report may fluctuate and investors may realize losses on any investments. Past performance is not a guide for future performance. Actual results may differ materially from those set forth in projections. SSL has reviewed the report and, the current or historical information included here is believed to be reliable, the accuracy and completeness of which is not guaranteed. SSL endeavors to update on a reasonable basis the information discussed in this document/material/ report, but regulatory compliance or other reasons may prevent it from doing so. This report/document has been prepared by SSL based upon information available to the public and sources, believed to be reliable. No representation or warranty, express or implied is made that it is accurate or complete. The opinions expressed in this report are subject to change without notice and have no obligation to tell the clients when opinions or information in this report change. This report has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India, United Kingdom or Singapore or by any Stock Exchange in India, United Kingdom or Singapore. This report may not be all inclusive and may not contain all the information that the recipient may consider material. This report does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced, transmitted or published by the recipient. The report is for the use and consumption of the recipient only. This report or any portion hereof may not be printed, sold or distributed without the written consent of SBICAP Entities. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. Distributing /taking/sending/dispatching/transmitting this document in certain foreign jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Failure to comply with this restriction may constitute a violation of any foreign jurisdiction laws. Neither SBICAP Entities nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Further, no representation or warranty, expressed or implied, is made or given by or on behalf of SBICAP Entities, nor any person who controls it or any director, officer, employee, advisor or agent of it, or affiliate of any such person or such persons as to the accuracy, authenticity, completeness or fairness of the information or opinions contained in this report and SBICAP Entities or such persons do not accept any responsibility or liability for any such information or opinions and therefore, any liability or responsibility is expressly disclaimed. Legal Entity Disclosure Singapore: This report may be distributed in Singapore by SBICAP (Singapore) Limited (Registration No R), a holder of a capital markets services license and an exempt financial adviser in Singapore and solely to persons who qualify as institutional investors or accredited investors (other than individuals) as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore (the SFA ) and is not intended to be distributed directly or indirectly to any other class of person. Persons in Singapore should contact SBICAP (Singapore) Limited in respect of any matters arising from, or in connection with this report. United Kingdom: This marketing communication is being solely issued to and directed at persons (i) fall within one of the categories of Investment Professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Financial Promotion Order ), (ii) fall within any of the categories of persons described in Article 49 of the Financial Promotion Order ( High net worth companies, unincorporated associations etc. ) or (iii) any other person to whom it may otherwise lawfully be made available (together Relevant Persons ) by SSL. The materials are exempt from the general restriction on the communication of invitations or inducements to enter into investment activity on the basis that they are only being made to Relevant Persons and have therefore not been approved by an authorised person as would otherwise be required by section 21 of the Financial Services and Markets Act 2000 ( FSMA ). This report is issued and distributed by SBICAP Entities without any liability / undertaking / commitment on the part of itselves or SBI Capital Markets Limited or State Bank of India or any other entity in the State Bank Group. Further, in case of any commitment on behalf of State Bank of India or SBI Capital Markets Limited or any entity in the State Bank Group, such commitment is valid only when separately confirmed by that entity. November 3,